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a prominent role in causing five neurodegenerative diseases, SMA, 
Huntington’s Disease (HD), Spinocerebellar Ataxias (SCAs), Fragile 
X–associated Tremor and Ataxia Syndrome (FXTAS) and some of 
the major subtypes of ALS (C9ORF72, TDP-43, FUS).
Extensive analysis of transcriptomes revealed that the expression 
levels and processing of hundreds to thousands of coding and non-
coding RNA molecules are affected during the course of RNA-
mediated neurodegeneration (reviewed in [7]). Given the large 
number of affected transcripts and their involvement in multiple 
cellular pathways, it is not feasible to investigate all of the gene 
expression changes and distinguish between those causing death of 
neurons and those arising from consequences of initial perturbations. 
Identifying the molecular mechanisms of neurodegeneration 
triggered by altered expression of genes remains in fact the main 
challenge in the RNA field of research. It considerably restricts 
the development of novel and effective therapeutic strategies of 
neuroprotection. The nature of biological samples further complicate 
the analysis of widespread RNA dysregulation as cell or animal 
models of neurodegenerative disorders and post-mortem tissue from 
patients might provide different results and directionality of changes 
depending on the disease stage, the fold expression of the transgene 
or the model organism. A typical conundrum for interpreting data 
from post-mortem tissue is to define whether gene expression 
changes are attributable to neurons that survived neurodegeneration 
or to neurons that were in the process of dying.
In general, new cell and animal models that better mimic the 
human neurological diseases and do not over express the mutated 
alleles are required. Technological advances derived from CRISPR-
Cas9 genome-editing approaches will allow the generation of novel 
cell and animal models based on chromosomal insertion of disease-
causing mutations (reviewed in [8]). This technology is also useful 
for the creation of isogenic controls by removing the disease-
causing mutations in patient-derived cells, taking thus away genetic 
variations in standard analysis that use healthy control individual 
and disease-affected patient-derived cells for the normalization of 
gene expression changes. Moreover, the expanding repertoire of 
protocols for the reprogramming of patient skin fibroblasts into 
various types of neurons, astrocytes or oligodendrocytes provide 
great opportunities to generate large amounts of neuronal materials, 
which are relevant to diseases and retain the aging-associated 
characteristics, for the biochemical investigation and genome-wide 
analysis of altered RNA molecules and proteins. On the other hand, 
the emerging next generation sequencing of RNA molecules isolated 
from single reprogrammed patient-derived cells appears to constitute 
a promising method with increased signal to noise ratios which allow 
for greater sensitivity in the identification of specific gene expression 
changes [9]. A key consideration remains to be taken into account. 
Most neurodegenerative diseases involve the progressive death of 
neurons with rapidly escalating motor and/or cognitive deficits 
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Editorial
The brain accounts for 2% of the body weight but consumes 
approximately 20% of the oxygen in the air breathed in as neurons 
heavily rely on the energy produced by oxidative phosphorylation. 
Increased reactive oxygen species and mitochondrial alterations 
are common features attributed to neurodegenerative diseases. The 
molecular mechanisms involved in the progressive death of neurons 
are however far more complex involving the additional dysregulation 
of multiple biological processes. These include the deposition 
of insoluble intracellular protein aggregates, the dysfunction of 
protein degradation and recycling pathways (ubiquitin/proteasome, 
autophagy/lysosomes), the swelling of axons and the induction 
of programmed cell death. Increasing evidence has also linked 
neurodegeneration to alterations of the RNA metabolism. In 
particular, pre-mRNA splicing defects were found to play key 
pathological roles due to reduced levels of SMN (Survival of Motor 
Neurons) in Spinal Muscular Atrophy (SMA) [1,2] and cytoplasmic 
mislocalisation/aggregation of TDP-43 (Transactive response DNA 
binding Protein of 43 kDa) in Frontotemporal Lobar Degeneration 
(FTLD) and in most cases of Amyotrophic Lateral Sclerosis (ALS) 
[3-6]. TDP-43 has since been involved in the regulation of multiple 
steps of gene expression which are all affected in neurodegeneration. 
These include miRNA biogenesis, transcriptional regulation, 
alternative splicing of conserved and non-conserved cryptic exons, 
axonal transport and stress-related translational control of mRNA. 
Widespread RNA dysregulation, with downstream alterations of 
coding and non-coding transcripts, has now been recognised to play 
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developing in late adulthood. Recent advances in the engineering 
of stable inducible cell and animal models might help address the 
progressive yet sudden onset nature of neurodegeneration. In these 
models, the transgene causing neuron injury is stably integrated at 
a defined chromosomal locus under the control of a tetracycline-
inducible promoter. Expression of the transgene and induction of 
disease is conveniently turned on at any time by the simple addition 
of tetracycline or derivatives into the tissue culture medium or the 
drinking water. These systems, which also allow building isogenic 
controls, provide powerful tools for identifying early events of 
dysregulation more likely to cause neuron injury and for monitoring 
the widespread consequences of initial transcript alterations over 
time.
The advent of transcriptomics and next generation sequencing 
technologies over the past 20 years has greatly improved our 
knowledge of the multifactorial processes that are involved in 
neuron injury. However, the mechanisms governing progressive 
death and age-related onset remain very poorly understood. Much 
more effort in a genomic medicine era is needed for the curation, 
the management, the integration and the optimal use of published 
data. This is increasingly relying on the development of interactable 
repositories for the sharing of expanding omics datasets and on 
user-friendly publically-available interfaces for personalized web-
searches and maximal exploitation of resources within the research 
community [10]. The biological interpretation of neurodegenerative 
transcriptomes has moreover been limited by the complexity of 
data and by the overwhelming number of differentially expressed 
transcripts with low fold changes. Is a 1.5-fold change pathologically 
more important than a 3-fold variation and when does statistical 
significance reach pathophysiological relevance are critical questions 
that usually remain unanswered. Another caveat concerns the 
directionality of gene expression changes. Up-regulation of mRNA 
levels does not necessarily correlate with increased levels of the 
corresponding proteins but often down regulation as cells compensate 
low levels of proteins by activating transcription. If thousands of 
altered transcripts have been characterized in neurodegeneration, 
the functional consequences of widespread RNA dysregulation 
remain largely unknown at the protein level. The proportion and 
identity of abnormally processed transcripts that are translated 
into non-physiological potentially neurotoxic proteins has yet to be 
investigated. Novel methodologies are emerging for the identification 
of translating RNA molecules (translatome, reviewed in [11,12]) and 
for measuring the synthesis rate of proteins (pulsed Stable Isotope 
Labeling with Amino acids in Cell culture (SILAC) proteome [13,14]).
This is a burgeoning and exciting field of research however these 
technologies remain practically complex and challenging as indicated 
by the very low number of publications. Optimization of the current 
methods and novel developments are required. Pulsed SILAC allows 
for partial investigation of the proteome (approximately 4,000 target 
proteins) and current translatome technologies do not necessarily 
discriminate between RNA molecules that are actively translated into 
proteins and RNA molecules indirectly associated to ribosomes via. 
other RNA-binding proteins or stress granules.
The mechanisms involved in RNA-mediated neurodegeneration 
also include non-conventional cellular pathways such as the 
unexpected discovery of Repeat-Associated Non-ATG (RAN) 
translation in SCA type 8 and Myotonic Dystrophy type 1 (DM1) 
[15]. Since, both non-coding and coding microsatellite repeat 
expansions in FXTAS [16], C9ORF72-related ALS [17] and HD [18] 
have been found to be translated in all reading frames leading to the 
production of polymeric repeat proteins with aggregating properties. 
The neurotoxicity-conferred by repeat proteins is complex involving 
nucleolar stress and the disruption of several cellular processes which 
include the altered nucleocytoplasmic transport of proteins and 
RNA as well as widespread defects in the nuclear processing of RNA. 
Repeat proteins complicate therefore the repertoire of widespread 
RNA dysregulation in neurodegeneration. On the other hand, they 
provide novel important therapeutic targets. The mechanisms of RAN 
translation are however yet poorly understood sparking enormous 
interest and focus in the field of microsatellite expansion disorders.
At the forefront of the discussed challenges and opportunities, 
the pace of RNA research in neurodegeneration and its translational 
applications are increasing with an explosion in the establishment of 
new research groups and publications over the past few years. This 
is a tremendously exciting area of research. Challenges are facing 
researchers each steps of their way from the understanding of the 
dysregulated mechanisms which cause progressive death of neurons, 
the engineering of new models of diseases, the development of novel 
technologies to the design and testing of new therapeutic strategies of 
neuroprotection. Investing in neurodegenerative research represents 
not only finding treatments to slow down or cure the relentless 
progression of neurological disorders - it is also about the huge 
impact on families, carers and society as well as on the potential 
discovery of other unknown cellular mechanisms that improve our 
general scientific understanding of life and disease.
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